Advertisement

Primary Pericardial Mesothelioma: A Population-Based Propensity Score-Matched Analysis

      Primary pericardial mesothelioma is a rare malignancy of the mesothelial lining of the pericardium. This study aimed to evaluate the clinical characteristics and survival outcomes of these patients using a United States population-based cancer database. We queried the Surveillance, Epidemiology, and End Results program (1973–2015). Primary pericardial mesothelioma patients with complete follow-up data were included, and primary pleural mesothelioma patients were identified as controls. Propensity-score matching was used to balance individual characteristics. Kaplan-Meier analysis and log-rank tests were performed to compare overall survival. Forty-one primary pericardial mesothelioma and 15,970 primary pleural mesothelioma patients were identified. Before matching, when compared to the pleural mesothelioma counterparts, primary pericardial mesothelioma patients were younger (median 57 vs 73 years, P < 0.001), more likely to be female (46.3% vs 20.2%, P < 0.001), more likely to be nonwhite (24.4% vs 8.4%, P = 0.001), and less likely to have been diagnosed in the most recent study decade (2006–2015, 34.1% vs 43.5%, P = 0.002). The overall 1- and 2-year survival rates were 22.0% and 12.2%, with a median survival of 2 months (IQR: 1-6). After 1:2 nearest neighbor propensity-score matching, 38 pericardial mesothelioma and 76 matched pleural mesothelioma cases were identified. The 2 matched groups had comparable baseline characteristics, including age, sex, race, year of diagnosis, histological type, and cancer history. Compared to their pleural mesothelioma counterparts, primary pericardial mesothelioma patients were less likely to receive chemotherapy (23.7% vs 50.0%, P = 0.01) and had worse overall survival (median survival: 2 vs 10 months, log-rank P = 0.006). Primary pericardial mesothelioma has worse survival outcomes than pleural mesothelioma, with a median survival of only 2 months. These patients should seek care from experienced multidisciplinary teams at tertiary care centers that handle high volumes of mesothelioma patients.

      Graphical Abstract

      Keywords

      Abbreviations:

      CI (confidence interval), IQR (interquartile range), MPM (malignant pleural mesothelioma), PCM (primary pericardial mesothelioma), SEER (Surveillance, Epidemiology, and End Results)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Li X.
        • Chen Y.
        • Liu J.
        • et al.
        Cardiac magnetic resonance imaging of primary cardiac tumors.
        Quant Imaging Med Surg. 2020; 10: 294-313
        • Elbardissi A.W.
        • Dearani J.A.
        • Daly R.C.
        • et al.
        Survival after resection of primary cardiac tumors: A 48-year experience.
        Circulation. 2008; 118: S7-S15
        • Sultan I.
        • Bianco V.
        • Habertheuer A.
        • et al.
        Long-term outcomes of primary cardiac malignancies: Multi-institutional results from the national cancer database.
        J Am Coll Cardiol. 2020; 75: 2338-2347
        • Papi M.
        • Genestreti G.
        • Tassinari D.
        • et al.
        Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
        Tumori. 2005; 91: 276-279
        • Kindler H.L.
        • Ismaila N.
        • Armato 3rd, S.G.
        • et al.
        Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
        J Clin Oncol. 2018; 36: 1343-1373
        • Freitas D.M.M.
        • Ramos R.L.
        • Serpa Pinto L.
        • et al.
        Primary pericardial mesothelioma and asbestos exposure: a rare fatal disease.
        BMJ Case Rep. 2017; 2017 (pii: bcr2017-219949)
        • Gössinger H.D.
        • Siostrzonek P.
        • Zangeneh M.
        • et al.
        Magnetic resonance imaging findings in a patient with pericardial mesothelioma.
        Am Heart J. 1988; 115: 1321-1322
        • Fernandes R.
        • Nosib S.
        • Thomson D.
        • Baniak N.
        A rare cause of heart failure with preserved ejection fraction: Primary pericardial mesothelioma masquerading as pericardial constriction.
        BMJ Case Rep. 2014; 2014bcr2013203194
        • Godar M.
        • Liu J.
        • Zhang P.
        • Xia Y.
        • Yuan Q.
        Primary pericardial mesothelioma: A rare entity.
        Case Rep Oncol Med. 2013; 2013283601
        • Suman S.
        • Schofield P.
        • Large S.
        Primary pericardial mesothelioma presenting as pericardial constriction: A case report.
        Heart. 2004; 90: e4
        • Mazurek J.M.
        • Syamlal G.
        • Wood J.M.
        • Hendricks S.A.
        • Weston A.
        Malignant mesothelioma mortality — United States, 1999–2015.
        MMWR Morb Mortal Wkly Rep. 2017; 66: 214-218
        • Bueno R.
        • Stawiski E.W.
        • Goldstein L.D.
        • et al.
        Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
        Nat Genet. 2016; 48: 407-416
      1. National Comprehensive Cancer Network. Malignant Pleural Mesothelioma (Version 2.2021). https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf. Accessed July 19, 2021.

        • Zalcman G.
        • Mazieres J.
        • Margery J.
        • et al.
        Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial.
        Lancet. 2016; 387: 1405-1414
        • Baas P.
        • Fennell D.
        • Kerr K.M.
        • Van Schil P.E.
        • Haas R.L.
        • Peters S.
        Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2015; 26: v31-v39
        • Maruyama R.
        • Sakai M.
        • Nakamura T.
        • et al.
        Triplet chemotherapy for malignant pericardial mesothelioma: A case report.
        Jpn J Clin Oncol. 2006; 36: 245-248
        • Pankaj G.
        • Ullas B.
        • Doval D.C.
        • et al.
        Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population.
        South Asian J Cancer. 2016; 5: 196-203
        • Dowell J.E.
        • Dunphy F.R.
        • Taub R.N.
        • et al.
        A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
        Lung Cancer. 2012; 77: 567-571
        • Feng X.
        • Zhao L.
        • Han G.
        • et al.
        A case report of an extremely rare and aggressive tumor: Primary malignant pericardial mesothelioma.
        Rare Tumors. 2012; 4: e21
        • Istomin V.
        • Blondheim D.S.
        • Meisel S.R.
        • Frimerman A.
        • Lapidot M.
        • Rachmilevitchet R.
        Pericardial effusion due to primary malignant pericardial mesothelioma: A common finding but an uncommon cause.
        Case Rep Med. 2016; 20164810901
        • Song G.
        • Bi W.
        • Zhang X.
        • Huang W.
        • Zhou K.
        • Ren W.
        Localized primary malignant pericardial mesothelioma.
        J Clin Ultrasound. 2019; 47: 178-181
        • Nilsson A.
        • Rasmuson T.
        Primary Pericardial Mesothelioma: Report of a patient and literature review.
        Case Rep Oncol. 2009; 2: 125-132
        • Amin W.
        • Linkov F.
        • Landsittel D.P.
        • et al.
        Factors influencing malignant mesothelioma survival: A retrospective review of the National Mesothelioma Virtual Bank cohort.
        F1000Res. 2018; 7: 1184
        • Pirracchio R.
        • Resche-Rigon M.
        • Chevret S.
        Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size.
        BMC Med Res Methodol. 2012; 12: 70
        • Cenzer I.
        • Boscardin W.J.
        • Berger K.
        Performance of matching methods in studies of rare diseases: A simulation study.
        Intractable Rare Dis Res. 2020; 9: 79-88
        • Yin K.
        • Luo R.
        • Wei Y.
        • et al.
        Survival outcomes in patients with primary cardiac sarcoma in the United States.
        J Thorac Cardiovasc Surg. 2021; 162: 107-115
        • Yin K.
        • Brydges H.
        • Lawrence K.W.
        • et al.
        Primary cardiac lymphoma.
        J Thorac Cardiovasc Surg. October 6, 2020; ([Epub ahead of print])

      Linked Article

      • Commentary: Limitations of Data for Primary Pericardial Mesothelioma
        Seminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
        • Preview
          Brydges and colleagues present a propensity-matched study of patients with primary pericardial mesothelioma (PCM) compared to patients with malignant pleural mesothelioma (MPM) based on SEER database from 1973 – 2015.1 Prior to matching, 41 patients with PCM were identified. The overall survivals (OS) were terrible with 22% and 12% surviving one and two years, respectively. With 1:2 propensity-matching, the authors found that patients with PCM were less likely to receive chemotherapy and had worse OS (2 versus 10 months).
        • Full-Text
        • PDF